Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of NOX-E36 in type 2 diabetes mellitus with albuminuria
2011-005710-11Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Dec 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and albuminuria comparing NOX-E36 with Placebo (2 arms). Primary endpoint: Change in albumin-creatinine ratio (ACR) from baseline to week 12. Started Dec 2011; status: completed.
02
Drugs
emapticap pegol
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuria
Beyond the preview
Go deeper on 2011-005710-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005710-11.